ABIGAIL MITZEL: Open Payments
NPI 1548037617 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,921 in 95 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $1,410 · 2025 $1,921
Food & beverage: $1,921
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $672 |
| Madrigal Pharmaceuticals | 7 | $262 |
| QOL Medical, LLC | 11 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $107 |
| Janssen Biotech, Inc. | 6 | $97 |
| Aimmune Therapeutics, Inc. | 5 | $95 |
| Gilead Sciences, Inc. | 3 | $88 |
| GENZYME CORPORATION | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 2 | $55 |
| Novo Nordisk Inc | 1 | $40 |
Products named: RINVOQ, REZDIFFRA, Sucraid, SKYRIZI, LINZESS, ENTYVIO, TREMFYA, ZENPEP.
Industry payments across NV — which companies pay providers there.
